doi: 10.1038/s41564-021-00884-1 105 PociotF
By targeting beta-3 adrenergic receptors in adipose tissue and initiating metabolic cascades that enhance fat breakdown, this growth hormone fragment provides fat-reducing benefits without affecting glucose metabolism, insulin sensitivity, or IGF-1 production
Published steady-state exposure puts 14 mg oral daily closer to a 0.5 mg weekly injection, and even 25 mg oral daily lands near a 0.9 mg weekly injection short of Wegovy 2.4 mg. Switching routes is an exposure change, not a brand swap
5-Amino-1MQ is not FDA approved as a standard treatment for anti-aging, fat loss, insulin resistance, cardiovascular disease, muscle recovery, or general wellness
For the dedicated scientific community ready to explore these frontiers responsibly, we're here to help you Get Started Today
Receiving B12 injections may delay a formal diagnosis of deficiency